Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian Population

Study Purpose:

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of 30,000 affected individual every year. Complex nature and unknown pathogenesis of this disease are 2 major reasons for failure of therapeutic interventions. Edaravone is a free radical scavenger that slows down functional decline and prevents from disease progression in ALS patients. FDA newly approved this drug in these patients (2017/5/5). In this study, investigators aimed to assess the treatment effect of this newly approved drug in patients with ALS in a representative Iranian population.

Study Status:

Not recruiting


Neuromuscular Diseases

Study Type:


Type of Intervention:


Intervention Name:

Edaravone, Riluzole




Phase 2/Phase 3

Study Chair(s)/Principal Investigator(s):



Neals Affiliated?


Coordinating Center Contact Information

Study Sponsor:

Isfahan University of Medical Sciences

Estimated Enrollment:


Estimated Study Start Date:

03 / 16 / 2017

Estimated Study Completion Date:

09 / 16 / 2019

Posting Last Modified Date:

03 / 27 / 2019

Date Study Added to

09 / 06 / 2017

Minimum Age:

18 Years

Maximum Age:

75 Years

Inclusion Criteria:

1. Patients diagnosed as definite or probable ALS according to El Escorial Criteria.

2. ALS patients who are graded as mild or moderate according to ALS Health State Scale.

3. Forced vital capacity of at least 80%

4. Desire of the patient to participate in this study and Signing Written Informed Consent.

Exclusion Criteria:

1. Incidence of drug's side effects that requires discontinuation of the drug (Edaravone's side effects: Acute kidney injury, Acute allergic reactions, DIC, Thrombocytopenia, Leukopenia).

2. Desire of the patient to discontinue participating in this study.

3. the patient starts another drug or herb for ALS during the study.

EMG Department, Alzahra Hospital

Iran, Islamic Republic of